WO2011090266A3 - 신규한 종양 항원 단백질 agr2및 이의 종양 항원성 펩티드 - Google Patents

신규한 종양 항원 단백질 agr2및 이의 종양 항원성 펩티드 Download PDF

Info

Publication number
WO2011090266A3
WO2011090266A3 PCT/KR2010/009213 KR2010009213W WO2011090266A3 WO 2011090266 A3 WO2011090266 A3 WO 2011090266A3 KR 2010009213 W KR2010009213 W KR 2010009213W WO 2011090266 A3 WO2011090266 A3 WO 2011090266A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
agr2
antigenic peptide
antigen protein
novel
Prior art date
Application number
PCT/KR2010/009213
Other languages
English (en)
French (fr)
Other versions
WO2011090266A2 (ko
Inventor
이제중
이현주
홍철이
박병철
Original Assignee
Lee Je Jung
Lee Hyun Ju
Hong Cheol Yi
Park Byung Chul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lee Je Jung, Lee Hyun Ju, Hong Cheol Yi, Park Byung Chul filed Critical Lee Je Jung
Publication of WO2011090266A2 publication Critical patent/WO2011090266A2/ko
Publication of WO2011090266A3 publication Critical patent/WO2011090266A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4634—Antigenic peptides; polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 신규한 종양 항원 단백질 AGR2 및 이의 종양 항원성 펩티드에 관한 것으로, 보다 상세하게는 상기 인간 AGR2(anterior gradient-2)종양 항원 단백질 또는 이의 항원성 펩티드가 탑재된 수지상세포 또는 이로부터 유도되는 AGR2 특이적 세포독성 T 림프구세포를 유효성분으로 하는 종양 치료 또는 예방용 세포 면역 치료제 조성물 및 이의 제조방법에 관한 것으로, 이는 수지상세포에 기초한 암면역세포치료에 있어서 강력한 종양 특이적인 세포옥성 면역반응을 유도하는 동시에 안전하고 부작용이 없는 암의 면역 치료용 백신으로 유용하게 이용될 수 있을 것이다.
PCT/KR2010/009213 2010-01-21 2010-12-22 신규한 종양 항원 단백질 agr2및 이의 종양 항원성 펩티드 WO2011090266A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0005405 2010-01-21
KR1020100005405A KR100982186B1 (ko) 2010-01-21 2010-01-21 신규한 종양 항원 단백질 ａｇｒ２ 및 이의 종양 항원성 펩티드

Publications (2)

Publication Number Publication Date
WO2011090266A2 WO2011090266A2 (ko) 2011-07-28
WO2011090266A3 true WO2011090266A3 (ko) 2011-11-24

Family

ID=43010114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/009213 WO2011090266A2 (ko) 2010-01-21 2010-12-22 신규한 종양 항원 단백질 agr2및 이의 종양 항원성 펩티드

Country Status (2)

Country Link
KR (1) KR100982186B1 (ko)
WO (1) WO2011090266A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102397922B1 (ko) 2020-02-19 2022-05-13 서울대학교 산학협력단 신규한 종양-관련 항원 단백질 olfm4 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087818A1 (en) * 2001-02-02 2003-05-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2004031239A2 (en) * 2002-10-02 2004-04-15 The University Of Liverpool Metastasis inducing compounds
WO2005001126A1 (en) * 2003-06-12 2005-01-06 Korea Research Institute Of Bioscience And Biotechnology Detection kit for gastric cancer and metastatic gastric cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087818A1 (en) * 2001-02-02 2003-05-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2004031239A2 (en) * 2002-10-02 2004-04-15 The University Of Liverpool Metastasis inducing compounds
WO2005001126A1 (en) * 2003-06-12 2005-01-06 Korea Research Institute Of Bioscience And Biotechnology Detection kit for gastric cancer and metastatic gastric cancer

Also Published As

Publication number Publication date
WO2011090266A2 (ko) 2011-07-28
KR100982186B1 (ko) 2010-09-14

Similar Documents

Publication Publication Date Title
PH12019502194A1 (en) Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
CR20200593A (es) NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295)
PH12017500484A1 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
CR20210035A (es) PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y CÉLULAS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE VEJIGA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0398)
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
SG10201807588TA (en) Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
SG10201806839PA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201004575D0 (en) Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
EP3456339A3 (en) Novel immunotherapy against several tumors, such as lung cancer including nsclc
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2006037421A3 (en) Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
WO2009015842A3 (en) Novel immunogenic epitopes for immunotherapy
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
WO2009102909A3 (en) Anti-cancer vaccines
WO2014004385A3 (en) Anti-cancer vaccines
WO2021094562A3 (en) Antigenic peptides for prevention and treatment of b-cell malignancy
WO2005067460A3 (en) Epha2 vaccines
PH12018501723A1 (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
EP3988563A3 (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
WO2011090266A3 (ko) 신규한 종양 항원 단백질 agr2및 이의 종양 항원성 펩티드
MX2020011791A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
WO2013040547A3 (en) Compounds and methods of immunization with tumor antigens
EA202190465A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10844062

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10844062

Country of ref document: EP

Kind code of ref document: A2